Management of lipids in primary and secondary prevention of cardiovascular diseases (Q39643034)

13 September 2017

1 reference

title

Management of lipids in primary and secondary prevention of cardiovascular diseases (English)

1 reference

13 September 2017

main subject

cardiovascular disease

1 reference

0 references

C J Lavie

1

1 reference

13 September 2017

G T Gau

series ordinal

2

1 reference

13 September 2017

R W Squires

series ordinal

3

1 reference

13 September 2017

B A Kottke

series ordinal

4

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 June 1988

1 reference

13 September 2017

1 reference

13 September 2017

volume

63

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

605-621

1 reference

Prevention of cardiovascular disease. Of what value are risk factor modification, exercise, fish consumption, and aspirin therapy?

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

A receptor-mediated pathway for cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cholesterol and coronary heart disease. A new era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Overview: extending the indications for treating hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The pathogenesis of atherosclerosis--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Consensus conference. Lowering blood cholesterol to prevent heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cholesterol reduction and life expectancy. A model incorporating multiple risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The cholesterol saga: whither health promotion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Apoproteins B and A-I and coronary artery disease in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The plasma lipoproteins as risk factors: comparison of electrophoretic and ultracentrifugation results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary arterial narrowing by atherosclerotic plaque in coronary heart disease. Quantitative analysis of 2,037 five mm segments of 160 major epicardial coronary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The triglyceride issue: a view from Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Lipid markers for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

High-density lipoproteins: epidemiologic profile and risks of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Lipid regulation: a clinician's view of patient management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfractions. A controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Apolipoproteins and coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Assessment of long-term plasma exchange for familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

National Cholesterol Education Program: does the emperor have any clothes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Dietary therapy for different forms of hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cholesterol-Lowering Effects of Psyllium Hydrophilic Mucilloid for Hypercholesterolemic Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The role of exercise training in the therapy of hyperlipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Current pharmacologic treatment of elevated serum cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Influence of gemfibrozil on high-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effects of probucol on xanthomata regression in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Studies on the mechanism of action of probucol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

A prospective study of postmenopausal estrogen therapy and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Menopause and the risk of coronary heart disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cholesterol and mortality in New Zealand Maoris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Plasma lipids and mortality: a source of error

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Serum cholesterol and cancer mortality in the Seven Countries Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cholesterol and mortality. 30 years of follow-up from the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years. Experience of an international collaborative group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Relation between the frequency of colorectal adenoma and the serum cholesterol level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Left ventricular hypertrophy--good or evil?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Prevalence and natural history of electrocardiographic left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Identification and treatment of diastolic dysfunction: role of transmitral Doppler recordings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Left atrial abnormalities indicating diastolic ventricular dysfunction in cardiopathy of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Antihypertensive therapy and lipids. Evidence, mechanisms, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Calcium blocker diltiazem inhibits platelet activation and stimulates vascular prostacyclin synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effects of verapamil on platelet aggregation, ATP release and thromboxane generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Marine fish oils: role in prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

The inverse relation between fish consumption and 20-year mortality from coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Cod-liver oil, platelet fatty acids, and bleeding time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2964891-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)64891-5

1 reference

13 September 2017

1 reference